Evidence map›Paper›PMID 12517830›Full record

ArticleJournal of clinical microbiology2003

Regional distribution of antibodies to herpes simplex virus type 1 (HSV-1) and HSV-2 in men and women in Ontario, Canada.

Michelle Howard, John W Sellors, Dan Jang, Noah J Robinson, Margaret Fearon, Janusz Kaczorowski, Max Chernesky

Open access · greenAbstract read
In one paragraph

Article in Journal of clinical microbiology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2023
    Article
  4. Hypertrophic herpes simplex virus 2 infection resistant to acyclovir in an immunosuppressed patient.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. What is new from the Canadian Paediatric Society Committee on Infectious Diseases and Immunization?The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2014
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Genital herpes in Canada: Deciphering the hidden epidemic.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2012
    Article
  18. Article
  19. Article
  20. Safety of antiviral medication for the treatment of herpes during pregnancy.Canadian family physician Medecin de famille canadien · 2011
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Michelle HowardDepartment of Family Medicine, McMaster University, Hamilton, Ontario, Canada. mhoward@mcmaster.ca
John W Sellors
Dan Jang
Noah J Robinson
Margaret Fearon
Janusz Kaczorowski
Max Chernesky
Cancer Research And Biostatistics · USSt. Joseph’s Healthcare Hamilton · CAGlaxoSmithKline (United Kingdom) · GBMinistry of Health and Long Term Care · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study estimated the regional and age- and gender-specific seroprevalences of herpes simplex virus type 1 (HSV-1) and HSV-2 in Ontario, Canada. Stored serum specimens from subjects aged 15 to 44 years, including men (n = 979), women not under prenatal care (n = 638), and women under prenatal care (n = 701) submitted for routine viral serology were randomly selected according to regional population size from public health laboratories. HSV-1 and HSV-2 testing was done with the MRL enzyme immunoassay (EIA) (Focus Technologies), and HSV-2 was also tested by the Gull/Meridian EIA. Specimens discordant for HSV-2 antibodies between the two EIAs were resolved by a recombinant immunoblot assay (Focus Technologies). The overall age- and gender-standardized seroprevalences of HSV-1 and HSV-2 were 51.1% (95% confidence interval [CI], 50.1 to 52.1) and 9.1% (95% CI, 8.6 to 9.7), respectively. The seroprevalence of HSV-1 antibodies increased from 26.9 to 54.7% in men between 15 to 16 and 40 to 44 years of age, from 32.0 to 88.7% in women not under prenatal care, and from 55.2 to 69.2% in women under prenatal care. The seroprevalence of HSV-2 increased from 3.8 to 21.3% in men between 15 to 16 and 40 to 44 years of age, from 0 to 18.9% in women not under prenatal care, and from 3.4 to 23.1% in women under prenatal care. HSV-2 results were discordant for 3.3% (76 of 2,318) of specimens. Both types of HSV antibodies appeared to be acquired earlier among women under prenatal care than among men and women not under prenatal care. Antibodies were more prevalent among people in northern Ontario (72.9% of subjects [range, 68.4 to 77.4%] for HSV-1 and 13.7% of subjects [95% CI, 10.2 to 17.2%] for HSV-2) than elsewhere.

Indexed as

AdolescentAdultAge DistributionAntibodies, ViralCanadaFemaleHerpes SimplexHerpesvirus 1, HumanHerpesvirus 2, HumanHumansImmunoenzyme TechniquesMalePrenatal CareSeroepidemiologic StudiesAntibodies, Viral

Identifiers

PMID12517830
PMCPMC149555
OpenAlexW2139080354

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.